ETNB - Rasio utang marang kapitalisasi buku 89bio Inc

The 89bio, Inc. (ETNB) price chart on the GURU.Markets platform illustrates the price action of the asset, which is currently valued at 0.07. The business focuses on developing Pegozafermin, an innovative treatment for fatty liver disease based on modified FGF21. The development model anticipates high margins driven by formula patenting, while supply reliability is ensured through the use of specialized cold-chain transportation.

ETNB (89bio Pharma) riwayat Utang marang nilai buku saka 04.07.2022 nganti 15.11.2025

89bio Inc (ETNB) - rincian metrik lan laporan keuangan

- rega lan prakiraan konsensus rega:

Rega saham 89bio, Inc.|ETNB - Prakiraan konsensus analis

- data kapitalisasi pasar:

Nilai pasar 89bio Pharma|ETNB - Nilai Dipunlarasaken Utang lan Kas

- data kapitalisasi buku:

Aset Bersih saben Siji Saham 89bio|ETNB - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku 89bio.com|ETNB - Total Aset Perusahaan

- data utang lan likuiditas:

Rasio Total Utang marang Ekuitas 89bio, Inc.|ETNB - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas 89bio Corp|ETNB - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku 89bio Pharma

Analisis fundamental perusahaan:89bio, Inc. - ETNB

This indicator determines the proportion of borrowed capital relative to the total value of assets minus liabilities, reflecting the extent to which the balance sheet structure depends on credit resources. For 89bio, Inc. (ETNB), the total debt-to-book capitalization ratio serves as a marker of financial stability when scaling operations with external research centers, where an increase in debt may indicate a search for liquidity to diversify the vendor pool.

Pesaing 89bio, Inc. (ETNB)